Cargando…
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
BACKGROUND: In locally advanced Non-Small-Cell Lung Cancer (LA-NSCLC) patients treated with chemoradiotherapy (CRT), optimal surrogate endpoint for cure has not been fully investigated. METHODS: The clinical records of LA-NSCLC patients treated with concurrent CRT at Shizuoka Cancer Center between S...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901557/ https://www.ncbi.nlm.nih.gov/pubmed/24422706 http://dx.doi.org/10.1186/1471-2407-14-18 |